ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that the Company has received funding from The National Institute of Health (“NIH”) to develop a culturally sensitive AI approach for collecting family medical history.

Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families. Current methods used by clinicians to collect family medical histories often do not satisfactorily capture important information from blended families or non-traditional relationships commonly found in racial or ethnic minority communities. The historical trauma and systemic bias common in African American communities can limit the amount of information known about the health of relatives. Without better methods for capturing information, existing health disparities addressing prevention and risk can persist. In collaboration with Rush River Research, Treatment is using its proprietary artificial intelligence capabilities to change how family health is collected and recorded to address existing disparities. The Company held multiple focus groups with African American doctors and community members to help develop and prototype culturally sensitive approaches to collecting information about family health.

As part of their work building the world’s most comprehensive and integrated online medical library powered by AI (the Global Library of Medicine), Treatment is aggressively acting to ensure that diagnostic and treatment information in the future will be provided by platforms that are free of the inequity commonly reflected in medical AI programs today. By convening focus groups of African Americans to evaluate Treatment’s platform and provide insights and suggestions, the company ensures a rich and diverse perspective will inform the platform’s continuous improvement.

The family history solution has been initially developed through a prototype that integrates into the Treatment AI platform. As continued improvements in the solution are made, they will be provided to Treatment for testing and implementation into future generations of the Global Library of Medicine platform.

Treatment and Rush River Research have recently submitted an expanded Phase 2 grant proposal to the NIH to extend the work. The goal of the proposal is to move the prototype into a commercial solution which will promote adoption and integration into electronic health records and online apps. 

Kevin Peterson MD, MPH, FRCS(Ed), FAAFP, Chief Medical Officer, stated: “Old data approaches inevitably reflect old biases. Treatment confronts issues of historical bias by reinventing how data about families is collected and stored to reflect the realities of modern life.”

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

ehamza@treatment.com

If you would like to find out more about Treatment’s products and services, please email: info@treatment.com

For media enquiries contact: media@treatment.com

Call: +1 (612) 788-8900 / Toll Free USA/Canada: +1 (888) 788-8955

Cautionary Statements

This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.


 

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.17
+2.20 (0.97%)
AAPL  269.06
+0.25 (0.09%)
AMD  258.07
-1.60 (-0.61%)
BAC  52.85
-0.17 (-0.32%)
GOOG  268.49
-1.44 (-0.53%)
META  751.36
+0.53 (0.07%)
MSFT  542.27
+10.75 (2.02%)
NVDA  201.07
+9.58 (5.00%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.54
+8.12 (1.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.